GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (NAS:EYPT) » Definitions » Cyclically Adjusted Revenue per Share

EyePoint Pharmaceuticals (EyePoint Pharmaceuticals) Cyclically Adjusted Revenue per Share : $2.54 (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is EyePoint Pharmaceuticals Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

EyePoint Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2024 was $0.221. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $2.54 for the trailing ten years ended in Mar. 2024.

During the past 12 months, EyePoint Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was -0.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -8.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -21.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of EyePoint Pharmaceuticals was 3.40% per year. The lowest was -39.00% per year. And the median was -15.50% per year.

As of today (2024-05-16), EyePoint Pharmaceuticals's current stock price is $12.94. EyePoint Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $2.54. EyePoint Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 5.09.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of EyePoint Pharmaceuticals was 11.03. The lowest was 0.90. And the median was 3.03.


EyePoint Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for EyePoint Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

EyePoint Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.17 2.47 2.40 2.53 2.61

EyePoint Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.56 2.59 2.62 2.61 2.54

Competitive Comparison of EyePoint Pharmaceuticals's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, EyePoint Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EyePoint Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



EyePoint Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, EyePoint Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.221/129.4194*129.4194
=0.221

Current CPI (Mar. 2024) = 129.4194.

EyePoint Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.100 100.560 0.129
201409 8.225 100.428 10.599
201412 0.177 99.070 0.231
201503 0.112 99.621 0.146
201506 0.134 100.684 0.172
201509 0.158 100.392 0.204
201512 0.179 99.792 0.232
201603 0.097 100.470 0.125
201606 0.089 101.688 0.113
201609 0.081 101.861 0.103
201612 1.747 101.863 2.220
201703 0.172 102.862 0.216
201706 0.181 103.349 0.227
201709 0.098 104.136 0.122
201712 0.210 104.011 0.261
201803 0.203 105.290 0.250
201806 0.129 106.317 0.157
201809 0.065 106.507 0.079
201812 0.287 105.998 0.350
201903 0.211 107.251 0.255
201906 0.679 108.070 0.813
201909 0.235 108.329 0.281
201912 0.795 108.420 0.949
202003 0.648 108.902 0.770
202006 0.330 108.767 0.393
202009 1.227 109.815 1.446
202012 0.491 109.897 0.578
202103 0.296 111.754 0.343
202106 0.314 114.631 0.355
202109 0.315 115.734 0.352
202112 0.353 117.630 0.388
202203 0.249 121.301 0.266
202206 0.310 125.017 0.321
202209 0.268 125.227 0.277
202212 0.282 125.222 0.291
202303 0.205 127.348 0.208
202306 0.242 128.729 0.243
202309 0.396 129.860 0.395
202312 0.332 129.419 0.332
202403 0.221 129.419 0.221

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


EyePoint Pharmaceuticals  (NAS:EYPT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

EyePoint Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=12.94/2.54
=5.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of EyePoint Pharmaceuticals was 11.03. The lowest was 0.90. And the median was 3.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


EyePoint Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


EyePoint Pharmaceuticals (EyePoint Pharmaceuticals) Business Description

Industry
Traded in Other Exchanges
Address
480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Executives
Ye Liu director ROOM 502-I, WANT WANT PLAZA, NO. 211 SHIMEN YI ROAD, SHANGHAI F4 200041
Dario A. Paggiarino officer: Chief Medical Officer 4025 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
Michael Craig Pine officer: Chief Corp Dev.&Strat. Officer C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, SUITE A-210, WATERTOWN MA 02472
Nancy Lurker director, officer: President and CEO PDI, INC., 1 ROUTE 17 SOUTH, SADDLE RIVER NJ 07458
Stuart Duty director 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Ew Healthcare Partners, L.p. 10 percent owner 21 WATERWAY AVENUE, SUITE 225, THE WOODLANDS TX 77380
Karen L. Zaderej director AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Anthony P Adamis director 3 TIMES SQUARE, 12TH FLOOR, NEW YORK NY 10036
Therapeutics Ocumension 10 percent owner 56F, ONE MUSEUM PLACE, 669 XIN ZHA ROAD, JING'AN DISTRICT, SHANGHAI F4 200041
George Elston officer: Chief Financial Officer 124 CHATHAM STREET, CHATHAM NJ 07928
Wendy F Dicicco director
David Scott Jones officer: SVP & Chief Commercial Officer C/O EYEPOINT PHARMACEUTICALS, INC.,, 480 PLEASANT STREET, SUITE A210, WATERTOWN MA 02472
John B. Landis director 1700 KENT AVENUE, WEST LAFAYETTE IN 46906
Jay S. Duker director C/O ELEVEN BIOTHERAPEUTICS, 215 1ST ST. #400, CAMBRIDGE MA 02142
Douglas Evan Godshall director SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000

EyePoint Pharmaceuticals (EyePoint Pharmaceuticals) Headlines